Cinctive Capital Management LP Sells 78,272 Shares of Edwards Lifesciences Corporation $EW

Cinctive Capital Management LP lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 50.1% during the third quarter, Holdings Channel reports. The firm owned 77,956 shares of the medical research company’s stock after selling 78,272 shares during the quarter. Cinctive Capital Management LP’s holdings in Edwards Lifesciences were worth $6,063,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in shares of Edwards Lifesciences by 111.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after buying an additional 4,805,819 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after acquiring an additional 4,108,270 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Edwards Lifesciences by 127.5% during the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock valued at $539,303,000 after acquiring an additional 3,864,908 shares in the last quarter. Finally, Viking Global Investors LP purchased a new stake in Edwards Lifesciences in the third quarter worth $238,688,000. Institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total transaction of $87,002.22. Following the completion of the transaction, the vice president owned 33,934 shares of the company’s stock, valued at approximately $2,897,284.92. This trade represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the transaction, the vice president owned 21,266 shares of the company’s stock, valued at $1,782,941.44. The trade was a 53.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 61,718 shares of company stock valued at $5,236,281 in the last three months. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

EW opened at $81.82 on Friday. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The company has a market cap of $47.52 billion, a price-to-earnings ratio of 44.71, a price-to-earnings-growth ratio of 2.13 and a beta of 0.93. The stock has a fifty day simple moving average of $82.41 and a two-hundred day simple moving average of $81.58. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on EW shares. TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Citigroup reaffirmed a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Royal Bank Of Canada lifted their target price on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, December 5th. Finally, Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a research report on Monday, January 12th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.